A Critical Review of the Effectiveness of Rodent Pharmaceutical Carcinogenesis Testing in Predicting for Human Risk
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The pharmaceutical industry and regulatory agency toxicology testing paradigms in the United States currently appear successful, in part because of the continuously increasing life expectancy and the declining age-adjusted cancer rates in the United States. Although drugs likely have a minimal impact on the population statistics for cancer rates, pharmaceutical pathologists and toxicologists must focus on the individual risk for pharmaceutical carcinogenesis. As our understanding of carcinogenesis increases exponentially, and after hundreds if not thousands of rodent cancer tests, significant improvement in the precision of human pharmaceutical carcinogenesis hazard identification should now be possible and would enable a reduction in the substantial false-negative and false positive-rates reported herein. The appropriate use of acute, subchronic, chronic, and special toxicology tests to identify the major associated cancer risk factors, specifically, hormonal modulation, immunosuppression, genetic toxicity, and chronic toxicity, can be recognized through this review of pharmaceutical carcinogens. Significant opportunities exist for improving the effectiveness and efficiency of the current cancer risk assessment paradigm.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, the 4 references (comprising 6 studies) with sample sizes over 200 all fall within this category [68–71].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [68]
Citations
Cites
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-92-3-460_4 · Cited by 4,529
An Improved Bacterial Test System for the Detection and Classification of Mutagens and Carcinogens
Ames, B. N., Lee, F. D., & Durston, W. E. (1973) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.70.3.782 · Cited by 1,532
Heron, M. P., Hoyert, D. L., Murphy, S. L., Xu, J., Kochanek, K. D., & Tejada‐Vera, B. (2009) · PubMed · Cited by 909
A new class of murine leukemia virus associated with development of spontaneous lymphomas.
Hartley, J. W., Wolford, N. K., Old, L. J., & Rowe, W. P. (1977) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.74.2.789 · Cited by 710
Robbins Pathologic Basis of Disease
Morrison, A. B. (1999) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.282.18.1776-a · Cited by 668
Chronic Inflammation and Cancer
Oshima, M. (2013) · 肥満研究 · Cited by 580
Chemical carcinogenesis: too many rodent carcinogens.
Ames, B. N., & Gold, L. S. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.19.7772 · Cited by 489 · cited 2×
“Specifically, an MTD bioassay does not distinguish between human carcinogens and noncarcinogens, but rather, it fails to detect the weak tumorigens at MTD.8 Given the standard sample size of 50, the lack of power to detect weak carcinogenic influences can be defined; an incidence of less than 10% is probably not detec…”
BackgroundProlactin and murine mammary tumorigenesis: a review.
Welsch, C. W., & Nagasawa, H. (1977) · PubMed · Cited by 466
The role of transgenic mouse models in carcinogen identification.
Pritchard, J. B., French, J. E., Davis, B. J., & Haseman, J. K. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.5778 · Cited by 138 · cited 3×
“Of course, the rat and mouse lifetime responses predict for rat and mouse carcinogenicity, thus predicting with precise accuracy for possible (Group 2B) human carcinogens, since all positive rodent responses are automatically classified as Group 2B by IARC and NTP, even in the absence of plausibility.(30,32) The rasH2…”
BackgroundMethodHuman Carcinogenic Risk Evaluation: An Alternative Approach to the Two-Year Rodent Bioassay
Cohen, S. M. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh159 · Cited by 132 · cited 4×
“which stimulates tumor development over the rodents’ lifespan.(7,14) Other rodent-specific carcinogenic endocrine feedback mechanisms involving adrenal cortex/medulla, pituitary, pancreas, and gastrointestinal endocrine cells.”
BackgroundInfluentialData quality in predictive toxicology: reproducibility of rodent carcinogenicity experiments.
Gottmann, E., Kramer, S., Pfahringer, B., & Helma, C. (2001) · Environmental Health Perspectives · doi:10.1289/ehp.01109509 · Cited by 127 · cited 1×
“In an extensive assessment of the repeatability of rodent cancer bioassays, results from only 57% of 121 replicates were identified as repeatable, indicating that rodent carcinogenicity assays are poorly reproducible.(20) The lack of repeatability can also be seen in this review of the PDR, for example, in the testing…”
BackgroundScreening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up.
Selby, J. V., FRIEDMAN, G. D., & FIREMAN, B. H. (1989) · PubMed · Cited by 122
p53 +/- Hemizygous Knockout Mouse: Overview of Available Data
Storer, R. D., French, J. E., Haseman, J., Hajian, G., LeGrand, E. K., Long, G. G., Mixson, L. A., Ochoa, R., Sagartz, J. E., & Soper, K. A. (2001) · Toxicologic Pathology · doi:10.1080/019262301753178465 · Cited by 104 · cited 2×
“Thus, the presence of evidence of hormonal modulation in toxicology studies should probably engender a warning for cancer hazard or further testing in a transgenic mouse carcinogenicity assay.(39)”
BackgroundGreaves, P. (2012) · Elsevier eBooks · doi:10.1016/b978-0-444-53856-7.00012-9 · Cited by 98
A Review of Chronic Inhalation Studies with Mainstream Cigarett Smoke in Rats and Mice
Coggins, C. R. E. (1998) · Toxicologic Pathology · doi:10.1177/019262339802600301 · Cited by 92
Hutt, J. A., Vuillemenot, B. R., Barr, E. B., Grimes, M. J., Hahn, F. F., HOBBS, C. H., March, T. H., Gigliotti, A. P., Seilkop, S. K., Finch, G. L., et al. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi150 · Cited by 92
The Utility of Two Rodent Species in Carcinogenic Risk Assessment of Pharmaceuticals in Europe
Oosterhout, J. P. J. V., van der Laan, J. W., Waal, E. J. D., Olejniczak, K., Hilgenfeld, M., Schmidt, V. C., & Bass, R. (1997) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1996.1077 · Cited by 88 · cited 1×
“This high false-positive rate also has significant recognition among pharmaceutical regulatory agency staff.(40)”
BackgroundMarketed Human Pharmaceuticals Reported to be Tumorigenic in Rodents
Davies, T. S., & Monro, A. M. (1995) · Journal of the American College of Toxicology · doi:10.3109/10915819509008684 · Cited by 86 · cited 3×
“Data supporting this hypothesis have been published, and a further challenge to this hypothesis is in progress under the auspices of a large collaboration of pharmaceutical and regulatory toxicologists and pathologists.(17,33)”
BackgroundCarcinogenic properties of pharmaceutical agents evaluated in the IARC Monographs programme
Μαρσέλος, Μ., & Vainio, H. (1991) · Carcinogenesis · doi:10.1093/carcin/12.10.1751 · Cited by 70 · cited 1×
“Of course, the rat and mouse lifetime responses predict for rat and mouse carcinogenicity, thus predicting with precise accuracy for possible (Group 2B) human carcinogens, since all positive rodent responses are automatically classified as Group 2B by IARC and NTP, even in the absence of plausibility.(30,32) The rasH2…”
BackgroundHistopathology of Preclinical Toxicity Studies
(2007) · Elsevier eBooks · doi:10.1016/b978-0-444-52771-4.x5000-7 · Cited by 68
History of the Bioassay Program of the National Cancer Institute
Weisburger, E. K. (2015) · Progress in tumor research · doi:10.1159/000407260 · Cited by 59
Reddy, M. V., Sistare, F. D., Christensen, J. S., DeLuca, J. G., Wollenberg, G. K., & DeGeorge, J. J. (2010) · Veterinary Pathology · doi:10.1177/0300985810373242 · Cited by 52
Self-citationLung Tumorigenicity in A/J and rasH2 Transgenic Mice Following Mainstream Tobacco Smoke Inhalation
Curtin, G. M. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh175 · Cited by 48
Ennever, F. K., & Lave, L. B. (2003) · Regulatory Toxicology and Pharmacology · doi:10.1016/s0273-2300(03)00068-0 · Cited by 47 · cited 1×
“Although the NTP lifetime rodent bioassay has been described as the gold standard for predicting human carcinogenicity associated with chemicals in the environment, few attempts have been made to validate it against human carcinogenicity.(19) Since all positive rodent tests are classified by the NTP (and IARC) at mini…”
MethodA Critical Appraisal of the Value of the Mouse Cancer Bioassay in Safety Assessment
Alden, C. L., Smith, P. F., Piper, C. E., & Brej, L. (1996) · Toxicologic Pathology · doi:10.1177/019262339602400610 · Cited by 40 · cited 4×
“which stimulates tumor development over the rodents’ lifespan.(7,14) Other rodent-specific carcinogenic endocrine feedback mechanisms involving adrenal cortex/medulla, pituitary, pancreas, and gastrointestinal endocrine cells.”
BackgroundInfluentialSelf-citationStolley, P. D., & Zahm, S. H. (1995) · Environmental Health Perspectives · doi:10.1289/ehp.95103s8191 · Cited by 33 · cited 1×
“Identifying carcinogenic drugs is difficult because of the typically long latent period of cancer, the inability to distinguish drug-induced cancers from those induced by other agents and conditions, and the general lack of epidemiologic surveillance for drug-induced cancer.(38) However, a major clinical epidemiologic…”
BackgroundMacDonald, J. S. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh189 · Cited by 33 · cited 1×
“Although PPAR-a antagonists are recognized as potent trans-species rodent liver carcinogens, this pharmacologic activity is generally recognized to have no link with a human liver cancer response.(29) The likelihood that any of the drugs of enhanced concern in this ‘‘other’’ category are actually human carcinogens thu…”
BackgroundThe Two-Year Rodent Carcinogenesis Bioassay - Will It Survive?
Ward, J. M. (2007) · Journal of Toxicologic Pathology · doi:10.1293/tox.20.13 · Cited by 32 · cited 1×
“lovastatin, griseofulvin, sertraline, albuterol, cimetidine, gemfibrozil, and terazosin.(5,17,22,28,31,41) In several cases, the animal mode of action is recognized as not relevant for human cancer risk, including:”
BackgroundImmunosuppression and Cancer: The Ciclosporin Case
Ryffel, B., Mihatsch, M. J., & Fisher, G. L. (1992) · Drug and Chemical Toxicology · doi:10.3109/01480549209032293 · Cited by 30 · cited 1×
“The rodent carcinogenicity bioassay results for cyclosporine were reported to be negative in the peer-reviewed literature written by the sponsor.(35) As we revise historical interpretations on the basis of new knowledge and modify the label accordingly, this paper must be seen as suspect.”
BackgroundHagiwara, A., & Ward, J. M. (1986) · Fundamental and Applied Toxicology · doi:10.1016/0272-0590(86)90087-4 · Cited by 29 · cited 1×
“lovastatin, griseofulvin, sertraline, albuterol, cimetidine, gemfibrozil, and terazosin.(5,17,22,28,31,41) In several cases, the animal mode of action is recognized as not relevant for human cancer risk, including:”
BackgroundACCELERATED DEVELOPMENT OF SPONTANEOUS THYMIC LYMPHOMAS IN MALE AKR MICE RECEIVING CYCLOSPORINE
Hattori, A., Perera, M. I. R., WITKOWSKI, L. A., Kunz, H. W., GILL, T. J., & Shinozuka, H. (1986) · Transplantation · doi:10.1097/00007890-198606000-00024 · Cited by 28
Confounded Carcinogenicity Study of Sodium Fluoride in CD-1 Mice
Maurer, J. K., Cheng, M., Boysen, B. G., Squire, R. A., Strandberg, J. D., Weisbrode, S. E., Seymour, J. L., & Anderson, R. L. (1993) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1993.1050 · Cited by 24 · cited 1×
“lovastatin, griseofulvin, sertraline, albuterol, cimetidine, gemfibrozil, and terazosin.(5,17,22,28,31,41) In several cases, the animal mode of action is recognized as not relevant for human cancer risk, including:”
BackgroundEarly indicators of exocrine pancreas carcinogenesis produced by non-genotoxic agents
Woutersen, R. A., van Garderen‐Hoetmer, A., Lamers, C. B. H. W., & Scherer, E. E. (1991) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/0027-5107(91)90063-t · Cited by 18 · cited 1×
“mediated by a chronically up-regulated cholecystokinin (CCK) hormonal proliferative stimulus.(11,44)”
Background2-year Toxicity Study of Doxylamine Succinate in the Fischer 344 Rat
Jackson, C. D., & Blackwell, B. (1993) · Journal of the American College of Toxicology · doi:10.3109/10915819309140617 · Cited by 17 · cited 1×
“lovastatin, griseofulvin, sertraline, albuterol, cimetidine, gemfibrozil, and terazosin.(5,17,22,28,31,41) In several cases, the animal mode of action is recognized as not relevant for human cancer risk, including:”
BackgroundDethloff, L. A., Graziano, M. J., Goldenthal, E. I., Gough, A. W., & de la Iglesia, F. A. (1996) · Human & Experimental Toxicology · doi:10.1177/096032719601500410 · Cited by 10 · cited 2×
“Some epidemiologic studies of anti-epilepsy drugs have not corrected for this exposure.(18) The last of these 15 drugs was fenofibrate.”
BackgroundAssessment of immunosuppressant drug carcinogenicity: standard and alternative animal models
Hastings, K. L. (2000) · Human & Experimental Toxicology · doi:10.1191/096032700678815837 · Cited by 7
Ross, J., & Barrowman, J. A. (1987) · Gut · doi:10.1136/gut.28.suppl.197 · Cited by 4 · cited 1×
“mediated by a chronically up-regulated cholecystokinin (CCK) hormonal proliferative stimulus.(11,44)”
Background
Research works printed but not linked: 2
- Arias E: United States Life Tables, 2006. In: National Vital Statistics Reports, Division of Vital Statistics, vol. 8, doc no. 21; 2010.
- Rubin E, Farber JL: The liver and biliary tract. In: Pathology. JB Lippincott Co., Philadelphia, 1988.
Cited by
Animal to human translation: a systematic scoping review of reported concordance rates
Leenaars, C. H. C., Kouwenaar, C., Stafleu, F. R., Bleich, A., Ritskes-Hoitinga, M., De Vries, R. B. M., & Meijboom, F. L. B. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1976-2 · Cited by 314
“reviewed drug labels from the physicians’ desk reference, which they searched for any mention of terms related to carcinogenesis [68].”
An Analysis of Pharmaceutical Experience with Decades of Rat Carcinogenicity Testing
Sistare, F. D., Morton, D. G., Alden, C. L., Christensen, J. S., Keller, D. A., Jonghe, S. D., Storer, R. D., Reddy, M. V., Kraynak, A. R., Trela, B. A., et al. (2011) · Toxicologic Pathology · doi:10.1177/0192623311406935 · Cited by 155
Self-citationJacobs, M. N., Colacci, A., Corvi, R., Vaccari, M., Aguila, M. C., Corvaro, M., Delrue, N., Desaulniers, D. M., Ertych, N., Jacobs, A. C., et al. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02784-5 · Cited by 153
Comparative Study of Multitask Toxicity Modeling on a Broad Chemical Space
Sosnin, S., Karlov, D., Tetko, I. V., & Fedorov, M. V. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00685 · Cited by 102
3S - Systematic, systemic, and systems biology and toxicology
Smirnova, L. (2018) · ALTEX · doi:10.14573/altex.1804051 · Cited by 72
“Its adequacy to predict cancer risk in humans, however, is the subject of considerable debate (Gottmann et al., 2001; Alden et al., 2011; Knight et al., 2006a,b; Paules et al., 2011) (Tab.”
Background
Metadata
- Authors
- Alden, C. L., Lynn, A., Bourdeau, A., Morton, D., Sistare, F. D., Kadambi, V. J., & Silverman, L.
- Affiliations
- Takeda Oncology (United States) (US)
- Pfizer (United States) (US)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lynn, A.
- ORCID
- Sistare, F. D.
- Venue
- Veterinary Pathology
- Publisher
- SAGE Publications
- Published
- 2011-03-07
- Volume
- 48
- Issue
- 3
- Pages
- 772-784
- ISSN
- 0300-9858 (ISSN-L)
- 1544-2217
- OpenAlex
- W2132201383
- Cited by
- 69
- References
- 37
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 3 · 2023: 2 · 2022: 2 · 2021: 5 · 2020: 4 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 3 · 2015: 8 · 2014: 7 · 2013: 8 · 2012: 4
- FWCI
- 0.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Veterinary Pathology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Carcinogens and Genotoxicity Assessment
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Keywords
- rodent carcinogenicity testing, hazard identification, hormonal modulation, immunosuppression, genotoxicity, chronic toxicity, cancer risk assessment, drug safety testing
- MeSH terms
- Animals, Biological Assay, Humans, Risk Factors, Rodentia, Carcinogenicity Tests, Drug-Related Side Effects and Adverse Reactions
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.